Unique ID issued by UMIN | UMIN000029969 |
---|---|
Receipt number | R000033915 |
Scientific Title | A single arm study of efficay of bifidobacterium for chronic constipation |
Date of disclosure of the study information | 2017/11/15 |
Last modified on | 2021/08/30 12:45:04 |
A single arm study of efficay of bifidobacterium for chronic constipation
A feasile study of efficay of bifidobacterium for chronic constipation
A single arm study of efficay of bifidobacterium for chronic constipation
A feasile study of efficay of bifidobacterium for chronic constipation
Japan |
chronic constipation
Medicine in general | Gastroenterology |
Others
NO
To investigate the efficacy of bifidobacterium for chronic constipation
Efficacy
The change in JPAC-QOL score from pre-to after 8 weeks intervention
1,The comparison of JPAC-QOL score between at study entry,at 4 weeks drug intervention,at 8 weeks drug intervention and at 2 weeks after drug intervention(end of study)
2,The comparison of stool form,degree of sense of incomplete evacuation,degree of straining and frequency of internal use of rescue drugs between at study entry,at 4 weeks drug intervention,at 8 weeks drug intervention and at 2 weeks after drug intervention(end of study)
3, The change in profile of gut microbiome from pre-to after 8 weeks drug intervention
4,The drug compliance
5,The incidence rate of adverse events
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
bifidobacterium
20 | years-old | <= |
80 | years-old | > |
Male and Female
1, Patients who are diagnosed chronic constipation by ROME criteria
2, Patients who can exhibit their consent in a document
1, Patients who have bristol score 1 or 7
2, Patients who have fewer than one defecation per week
3, Patients who have obvious defecation disorders
4, Patients who have fewer than one of overall JPAC-QOL score
5, Patients who are excluded mechanical disorders by colonoscopy within five years
6, Patients who have severe complications
7, Patients who have history or current evidence of celiac disease or inflammatory bowel disease
8, Patients who are under treatment with steroid or biological products
9, Patients who have severe psychiatric disease
10, Patients who have current evidence of abuse of drugs or alcohol
11, Patients who have history of bifidobacteria allergies
12, Patients who had taken new drug therapy within 4 weeks before entry
13, Patients who had any change in types, dosage,or adiministration of their prescribed drugs within 4 weeks before entry
14, Patients who or are going to take new medicines
15, Patients who or are going to be participating in other clinical studies
16, Patients who are under treatment with other probiotics
17, Patients who are judged as inadequately for study entry
60
1st name | |
Middle name | |
Last name | Atsushi Nakajima |
Yokohama City University school of medicine
Department of gastroenterology and hepatology
3-9 Fukuura Kanazawa-ku Yokohama City
045-787-2640
nakajima-tky@umin.ac.jp
1st name | |
Middle name | |
Last name | Fuyuki Akiko |
Yokohama City University school of medicine
Department of gastroenterology and hepatology
3-9 Fukuura Kanazawa-ku Yokohama City
045-787-2640
fuyuki-sin@umin.ac.jp
Yokohama City University School of Medicine Department of Gastroenterology and Hepatology
Biofermin Pharmacutical Co.,Ltd
Profit organization
NO
2017 | Year | 11 | Month | 15 | Day |
Unpublished
Completed
2017 | Year | 06 | Month | 20 | Day |
2017 | Year | 06 | Month | 20 | Day |
2017 | Year | 11 | Month | 14 | Day |
2019 | Year | 03 | Month | 27 | Day |
2017 | Year | 11 | Month | 14 | Day |
2021 | Year | 08 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033915